Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Potestio

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|November 14, 2023
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response FactorsLuca Potestio, Cataldo Patruno, Maddalena Napolitano
Expert Review of Clinical Immunology|May 30, 2025
Psoriasis, pregnancy, and lactation: clinical implications and treatmentsMichela D'Agostino, Luca Potestio, Matteo Megna
Current Opinion in Allergy and Clinical Immunology|July 5, 2022
Clinical phenotypes of adult atopic dermatitis and related therapiesCataldo Patruno, Luca Potestio, Maddalena Napolitano
Expert Opinion on Biological Therapy|June 13, 2022
Treating psoriasis in the elderly: biologics and small moleculesMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Review of Clinical Immunology|January 9, 2024
Considerations for managing elderly patients with atopic dermatitisMaddalena Napolitano, Luca Potestio, Mariateresa Nocerino, et al.
Dermatology and Therapy|February 27, 2025
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa PatientFabrizio Martora, Teresa Battista, Luca Potestio, et al.
Psoriasis (Auckland, N.Z.)|July 21, 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective StudyMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Drugs in Context|June 29, 2026
Deucravacitinib in dermatology: current indication and existing off-label dataMichela D'Agostino, Luca Potestio, Nello Tommasino, et al.
Advances in Therapy|January 28, 2022
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell CarcinomaAlessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Archives of Dermatological Research|December 12, 2024
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective studyLuca Potestio, Angelo Ruggiero, Fabrizio Martora, et al.
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Dermatitis : Contact, Atopic, Occupational, Drug|November 14, 2023
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response FactorsLuca Potestio, Cataldo Patruno, Maddalena Napolitano
Expert Review of Clinical Immunology|May 30, 2025
Psoriasis, pregnancy, and lactation: clinical implications and treatmentsMichela D'Agostino, Luca Potestio, Matteo Megna
Current Opinion in Allergy and Clinical Immunology|July 5, 2022
Clinical phenotypes of adult atopic dermatitis and related therapiesCataldo Patruno, Luca Potestio, Maddalena Napolitano
Expert Opinion on Biological Therapy|June 13, 2022
Treating psoriasis in the elderly: biologics and small moleculesMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Review of Clinical Immunology|January 9, 2024
Considerations for managing elderly patients with atopic dermatitisMaddalena Napolitano, Luca Potestio, Mariateresa Nocerino, et al.
Dermatology and Therapy|February 27, 2025
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa PatientFabrizio Martora, Teresa Battista, Luca Potestio, et al.
Psoriasis (Auckland, N.Z.)|July 21, 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective StudyMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Drugs in Context|June 29, 2026
Deucravacitinib in dermatology: current indication and existing off-label dataMichela D'Agostino, Luca Potestio, Nello Tommasino, et al.
Advances in Therapy|January 28, 2022
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell CarcinomaAlessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Archives of Dermatological Research|December 12, 2024
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective studyLuca Potestio, Angelo Ruggiero, Fabrizio Martora, et al.
Pageof 14